Search

Your search keyword '"Yakoub‐Agha, Ibrahim"' showing total 30 results
Start Over Author "Yakoub‐Agha, Ibrahim" Language undetermined
30 results on '"Yakoub‐Agha, Ibrahim"'

1. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

Author

Snowden, John A., Sánchez-Ortega, Isabel, Corbacioglu, Selim, Basak, Grzegorz W., Chabannon, Christian, de la Camara, Rafael, Dolstra, Harry, Duarte, Rafael F., Glass, Bertram, Greco, Raffaella, Lankester, Arjan C., Mohty, Mohamad, Neven, Bénédicte, de Latour, Régis Peffault, Pedrazzoli, Paolo, Perić, Zinaida, Yakoub-Agha, Ibrahim, Sureda, Anna, Kröger, Nicolaus, and UAM. Departamento de Medicina

Subjects
Transplantation, Neoplasms / therapy, Medicina, Haematopoietic cell transplantation (HCT), Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Hematologic Diseases / therapy, Hematopoietic Stem Cell Transplantation, Hematology, Europe, Immune System Diseases / therapy, Immune disorders, HCT, Humans, Haematological diseases, Solid tumours, EBMT
Abstract

For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the eighth special EBMT report on the indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered in conjunction with the risk of the disease, risk of HCT procedure and non-transplant strategies, including evolving cellular therapies. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE accreditation standards to maintain quality in clinical and laboratory components of practice, including benchmarking of survival outcomes. Since the last edition, the COVID-19 pandemic has affected clinical decision making and activity across indications. Although the full impact of the pandemic is yet to be determined, we recommend that decision making across indications is delivered with ongoing reference to EBMT and national COVID-19 guidance, in accordance with current local conditions.

Published
2022

3. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Author

Carré, Martin, Porcher, Raphaël, Finke, Jürgen, Ehninger, Gerhard, Koster, Linda, Beelen, Dietrich, Ganser, Arnold, Volin, Liisa, Lozano, Sara, Friis, Lone, Michallet, Mauricette, Tischer, Johanna, Olavarria, Eduardo, Cascon, Maria Jesús Pascual, Iacobelli, Simona, Koc, Yener, Jindra, Pavel, Arat, Mutlu, de Witte, Theo, Yakoub Agha, Ibrahim, Kröger, Nicolaus, Robin, Marie, and Agha, Ibrahim Yakoub

Subjects
Adult, medicine.medical_specialty, Transplantation Conditioning, Multivariate analysis, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], medicine.medical_treatment, Myelodysplastic syndromes, Medizin, Comorbidity, Hematopoietic stem cell transplantation, Comorbidities, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Age, 0302 clinical medicine, Bone Marrow, Neoplasms, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Retrospective Studies, Transplantation, Nonrelapse mortality, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Hematology, Settore MED/15, medicine.disease, Settore MED/01, 030220 oncology & carcinogenesis, Stem cell, business, 030215 immunology
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative option for myelodysplastic syndromes (MDSs) but is severely limited by nonrelapse mortality (NRM), especially in this mostly older population. Comorbidity assessment is crucial to predict NRM and often assessed with the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI). Moreover, the impact of age on NRM still remains a matter of debate. In recent years, the age at which transplants are made has been progressively increasing, and patients with comorbidities have become more common. Extricating the respective roles of age and comorbidities in toxic mortality is all the more important. This study by the European Group for Blood and Marrow Transplantation registry included 1245 adult patients who underwent a first allogeneic stem cell transplantation for MDSs between 2003 and 2014. Overall, 4-year NRM and overall survival were 32% and 47%, respectively. When considered as continuous predictors, HCT-CI score and age were associated with an increased hazard ratio (HR) for NRM. In multivariate analysis, age band (HR, 1.13; 95% CI, 1.02 to 1.25; P= .016), HCT-CI ≥3 (HR, 1.34; 95% CI, 1.04 to 1.73; P = .022), and Karnofsky Performance Status ≤80 (HR, 2.03; 95% CI, 1.52 to 2.73; P.0001) were significantly predictive of a worse NRM. In our large cohort, both comorbidities, evaluated by the original HCT-CI score, and chronological age significantly affected NRM. Thus, age should be part of the transplant decision-making process and should be integrated in future scoring systems predicting outcomes of HSCT in MDSs.

Published
2020

4. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation

Author

Gagelmann, Nico, Eikema, Diderik-Jan, de Wreede, Liesbeth C, Koster, Linda, Wolschke, Christine, Arnold, Renate, Kanz, Lothar, McQuaker, Grant, Marchand, Tony, Socié, Gerard, Bourhis, Jean Henri, Mohty, Mohamad, Cornelissen, Jan J, Chevallier, Patrice, Bernasconi, Paolo, Stelljes, Matthias, Rohrlich, Pierre-Simon, Fanin, Renato, Finke, Jürgen, Maertens, Johan, Blaise, Didier, Itälä-Remes, Maija, Labussière-Wallet, Hélène, Robin, Marie, McLornan, Donal, Chalandon, Yves, Yakoub-Agha, Ibrahim, Kröger, Nicolaus, CMWP of the European Society for Blood and Marrow Transplantation, Hematology, and Medical Oncology

Subjects
Adult, medicine.medical_specialty, Essential thrombocythemia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Polycythemia vera, Internal medicine, Humans, Transplantation, Homologous, Medicine, Allogeneic stem cell transplantation, Secondary myelofibrosis, Hematology, Transplantation, Myelofibrosis, Polycythemia Vera, Survival analysis, Aged, ddc:616, Framingham Risk Score, business.industry, Hematopoietic Stem Cell Transplantation, Middle Aged, Prognosis, medicine.disease, Survival Analysis, Treatment Outcome, Primary Myelofibrosis, International Prognostic Scoring System, 030220 oncology & carcinogenesis, Cohort, business, Thrombocythemia, Essential, 030215 immunology
Abstract

We aimed to validate the MYelofibrosis SECondary to PV and ET prognostic model (MYSEC-PM) in 159 patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET) from the European Society for Blood and Marrow Transplantation registry undergoing transplantation from matched siblings or unrelated donors. Furthermore, we aimed to test its prognostic performance in comparison with the Dynamic International Prognostic Scoring System (DIPSS). Score performance was analyzed using the concordance index (C): the probability that a patient who experienced an event had a higher risk score than a patient who did not (C > .5 suggesting predictive ability). Median follow-up of the total cohort was 41 months (range, 34 to 54), 45 months in post-PV and 38 months in post-ET myelofibrosis. Survival at 1, 2, and 4 years was 70% (95% CI, 63% to 77%), 61% (95% CI, 53% to 69%), and 52% (95% CI, 43% to 61%) for the total cohort; 70% (95% CI, 59% to 80%), 61% (95% CI, 49% to 73%), and 51% (95% CI, 38% to 64%) for post-PV; and 71% (95% CI, 61% to 81%), 61% (95% CI, 50% to 72%), and 54% (95% CI, 42% to 66%) for post-ET myelofibrosis (P = .78). Overall, the DIPSS was not significantly predictive of outcome (P = .28). With respect to the MYSEC-PM, overall survival at 4 years was 69% for the low-risk, 55% for the intermediate 1-risk, 47% for the intermediate 2-risk, and 22% (0% to 45%) for the high-risk groups. The prognostic model was predictive of survival overall (P = .05), whereas groups with intermediate 2 and high risk showed no significant difference (P = .44). Assessment of prognostic utility yielded a C-index of .575 (95% CI, .502 to .648) for the DIPSS, whereas assessment of the MYSEC-PM resulted in a C-statistics of .636 (95% CI, .563 to .708), indicating improvement in prediction of post-transplant survival using the new MYSEC-PM. In addition, transplantations from an unrelated donor in comparison with an HLA-identical sibling showed worse outcome (P = .04), and transplant recipients seropositive for cytomegalovirus in comparison with seronegative recipients (P = .01) showed worse survival. In conclusion, incorporating transplant-specific and clinical and mutational information together with the MYSEC-PM may enhance risk stratification. ispartof: Biol Blood Marrow Transplant vol:25 issue:6 pages:e204-e208 ispartof: location:United States status: published

Published
2019

5. MOESM3 of Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

Author

Jiří Pavlů, Labopin, Myriam, Niittyvuopio, Riitta, Socié, Gerard, Yakoub-Agha, Ibrahim, Depei Wu, Remenyi, Peter, Passweg, Jakob, Beelen, Dietrich, Aljurf, Mahmoud, Kröger, Nicolaus, Labussière-Wallet, Hélène, Perić, Zinaida, Giebel, Sebastian, Nagler, Arnon, and Mohty, Mohamad

Subjects
hemic and lymphatic diseases
Abstract

Additional file 3. A. Univariate planned sub-analyses performed separately in subgroups of patients transplanted after chemotherapy-based and TBI-based conditioning. Abbreviations: GVHD, graft-versus-host disease; GRFS, GVHD-free and relapse-free survival; LFS, leukemia free survival; MRD, measurable residual disease; NRM, non-relapse mortality; OS, overall survival; RI, relapse incidence. B. Multivariate planned sub-analyses performed separately in subgroups of patients transplanted after chemotherapy-based conditioning (571 patients of whom 382 were MRD negative and 205 MRD positive) and TBI-based conditioning (1943 patients of whom 1278 were MRD negative and 680 MRD positive). Abbreviations: BM, bone marrow; CR, complete remission; CMV, cytomegalovirus; GVHD, graft-versus-host disease; GRFS, GVHD-free and relapse-free survival; KPS, Karnofsky performance score; LFS, leukemia free survival; MRD, measurable residual disease; NRM, non-relapse mortality; OS, overall survival; Ph, Philadelphia chromosome/BCR-ABL gene rearrangement; RI, relapse incidence; TCD, T-cell depletion; UD, unrelated donor.

Published
2019
Full Text
View/download PDF

6. MOESM2 of Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

Author

Jiří Pavlů, Labopin, Myriam, Niittyvuopio, Riitta, Socié, Gerard, Yakoub-Agha, Ibrahim, Depei Wu, Remenyi, Peter, Passweg, Jakob, Beelen, Dietrich, Aljurf, Mahmoud, Kröger, Nicolaus, Labussière-Wallet, Hélène, Perić, Zinaida, Giebel, Sebastian, Nagler, Arnon, and Mohty, Mohamad

Subjects
surgical procedures, operative
Abstract

Additional file 2. Univariate analysis of factors determining outcomes of transplantation at 2 years.

Published
2019
Full Text
View/download PDF

7. MOESM1 of Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT

Author

Jiří Pavlů, Labopin, Myriam, Niittyvuopio, Riitta, Socié, Gerard, Yakoub-Agha, Ibrahim, Depei Wu, Remenyi, Peter, Passweg, Jakob, Beelen, Dietrich, Aljurf, Mahmoud, Kröger, Nicolaus, Labussière-Wallet, Hélène, Perić, Zinaida, Giebel, Sebastian, Nagler, Arnon, and Mohty, Mohamad

Abstract

Additional file 1. List of all institutions reporting data included in this study.

Published
2019
Full Text
View/download PDF

8. Additional file 1: of Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Author

PoirĂŠ, Xavier, Labopin, Myriam, Maertens, Johan, Yakoub-Agha, Ibrahim, Blaise, Didier, Ifrah, Norbert, GĂŠrard SociĂŠ, Gedde-Dhal, Tobias, Schaap, Nicolaas, Cornelissen, Jan, StĂŠphane Vigouroux, Sanz, Jaime, Michaux, Lucienne, Esteve, Jordi, Mohty, Mohamad, and Nagler, Arnon

Abstract

Table S1. (DOCX 13 kb)

Published
2017
Full Text
View/download PDF

9. Additional file 1: Table S1. of Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party

Author

Rubio, Marie, D’Aveni-Piney, Maud, Labopin, Myriam, Rose-Marie Hamladji, Sanz, Miguel, Blaise, Didier, Ozdogu, Hakan, Daguindeau, Etienne, Richard, Carlos, Santarone, Stella, Irrera, Giuseppe, Yakoub-Agha, Ibrahim, Yeshurun, Moshe, Diez-Martin, Jose, Mohty, Mohamad, Bipin Savani, and Nagler, Arnon

Abstract

List of institutions reporting the patients’ data for the study. (DOCX 33 kb)

Published
2017
Full Text
View/download PDF

10. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood--a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation

Author

Baron, Frédéric, Labopin, Myriam, Ruggeri, Annalisa, Mohty, Mohamad, Sanz, Guillermo, Milpied, Noel, Bacigalupo, Andrea, Rambaldi, Alessandro, Bonifazi, Francesca, Bosi, Alberto, Sierra, Jorge, Yakoub-Agha, Ibrahim, Ribera, Jose-Maria, Gluckman, Eliane, Nagler, Arnon, Universitat Autònoma de Barcelona, Service d'Hématologie, Université de Liège-CHU Sart-Tilman, Centre International des greffes [CHU Saint-Antoine] (EBMT), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Eurocord, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Servicio de Hematologia, Hospital Universitari i Politècnic La Fe, Service d'Hématologie et Thérapie Cellulaire, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Department of Haematology II, Ospedale San Martino, Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Institute of Hematology and Medical, Oncology L and A Seràgnoli, Policlinico S. Orsola - Malpighi, Bone Marrow Transplant Unit (BMT), Azienda Ospedaliera Careggi, Hematology Department, Hospital de la Santa Creu i Sant Pau, Unités d'Activité Médicale [Lille] (UAM), Hôpital Claude Huriez [Lille], CHU Lille-CHU Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Jose Carreras Research Institute, Hospital Universitari Germans Trias i Pujol, France Monacord, Centre Scientifique de Monaco (CSM), Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center at Tel hashomer, Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe, BMC, BMC, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut Universitaire d'Hématologie (IUH), and Hôpital Claude Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

Subjects
Male, Cancer Research, [SDV]Life Sciences [q-bio], GVHD, Graft vs Host Disease, Blood Donors, 0302 clinical medicine, AML, Risk Factors, hemic and lymphatic diseases, Medicine, 0303 health sciences, Acute leukemia, Hematology, Incidence, Hazard ratio, Middle Aged, 3. Good health, Europe, Survival Rate, [SDV] Life Sciences [q-bio], Leukemia, surgical procedures, operative, Oncology, Leukemia, Myeloid, 030220 oncology & carcinogenesis, Cord blood, Acute Disease, Female, Cord Blood Stem Cell Transplantation, Adult, medicine.medical_specialty, Adolescent, 03 medical and health sciences, Young Adult, Sex Factors, Unrelated cord blood, Sang fetal, Internal medicine, Humans, Survival rate, Molecular Biology, 030304 developmental biology, Aged, Retrospective Studies, Transplantation, business.industry, Research, medicine.disease, Survival Analysis, Surgery, Multivariate Analysis, business
Abstract

Background In the setting of allogeneic human leukocyte antigen (HLA)-matched bone marrow transplantation, transplanting male patients with grafts from female donors has been associated with a higher incidence of graft-versus-host disease (GVHD) and of nonrelapse mortality (NRM). The aim of the current analysis was to compare transplantation outcomes in male patients given female unrelated cord blood (UCB) versus other gender combinations. Patients and methods Data from 552 consecutive patients with acute myeloid leukemia (AML) given a single UCB transplantation between 2000 and 2014 were included. Results In comparison with other gender combination, male patients given female UCB (n = 131) had a trend for a higher incidence of grades II–IV acute GVHD (33 versus 25 %, P = 0.08), a trend for a higher incidence of NRM (41 versus 33 %, P = 0.06), and a lower leukemia-free (LFS, 30 versus 41 %, P = 0.01) and overall survival (OS, 33 versus 45 %, P = 0.008). In multivariate analyses, taking into consideration all patients for which data on HLA-matching and cell dose transplanted were fully available (n = 363), male patients transplanted with a female UCB had a trend for a higher incidence of grade III–IV acute GVHD (hazard ratio (HR) = 2.0, P = 0.06), a trend for a higher NRM (HR = 1.5, P = 0.06), and a worse LFS (HR = 1.4, P = 0.04) and OS (HR = 1.3, P = 0.06). Conclusions Our data suggest that male patients transplanted with female UCB might have higher risk of acute GVHD and of NRM leading to worse LFS and OS. These results should be confirmed in other large cohorts of patients before used for determining the choice of an UCB unit. Electronic supplementary material The online version of this article (doi:10.1186/s13045-015-0207-4) contains supplementary material, which is available to authorized users.

Published
2015

11. Additional file 1: of Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord bloodâ a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation

Author

FrĂŠdĂŠric Baron, Labopin, Myriam, Ruggeri, Annalisa, Mohty, Mohamad, Sanz, Guillermo, Milpied, Noel, Bacigalupo, Andrea, Rambaldi, Alessandro, Bonifazi, Francesca, Bosi, Alberto, Sierra, Jorge, Yakoub-Agha, Ibrahim, Santasusana, Josep, Gluckman, Eliane, and Nagler, Arnon

Abstract

List of institutions reporting data in this study.

Published
2015
Full Text
View/download PDF

13. The role of renal impairment at diagnosis in multiple myeloma undergoing autologous transplantation. A retrospective analysis of the CMWP

Author

Scheid, Christof, Hoek, Jennifer, Russell, Nigel H., Didier Blaise, Mayer, Jiri, Ljungman, Per, Lenhoff, Stig, Kobbe, Guido, Iacobelli, Simona, Isaksson, Cecilia, Schaap, Nicolaas, Basak, Grzegorz, Hayden, Patrick, Gonzalez Muniz, Soledad, Apperley, Jane, Rambaldi, Alessandro, Wilson, Keith M. O., Parody Porras, Rocio, Jantunen, Esa, Anagnostopoulos, Achilles, Schoenland, Stefan, Yakoub-Agha, Ibrahim, Kroeger, Nicolaus, Morris, Curly, and Garderet, Laurent

14. Allogeneic Transplantation for Acute Myeloid Leukemia with Monosomy 7 or Deletion 7q: a Study from the Acute Leukemia Working Party (ALWP) of the EBMT

Author

Poire, Xavier, Labopin, Myriam, Polge, Emmanuelle, Volin, Liisa, Finke, Jurgen, Ganser, Arnold, Didier Blaise, Yakoub-Agha, Ibrahim, Beelen, Dietrich, Milpied, Noel, Ledoux, Marie-Pierre, Socie, Gerard, Niederwieser, Dietger, Michallet, Mauricette, Maertens, Johan, Cornelissen, Jan, Craddock, Charles, Mohty, Mohamad, Esteve, Jordi, and Nagler, Arnon

Subjects
Medizin

16. In Vivo Persistence of Human Rhinoviruses in Immunosuppressed Patients

Author

Engelmann, Ilka, Dewilde, Anny, Lazrek, Mouna, Batteux, Mathilde, Hamissi, Aminati, Yakoub-Agha, Ibrahim, and Hober, Didier

Subjects
RNA viruses, Male, 0301 basic medicine, Viral Diseases, Time Factors, Pulmonology, Rhinovirus, medicine.medical_treatment, lcsh:Medicine, Pathology and Laboratory Medicine, medicine.disease_cause, Enteroviruses, Persistence (computer science), Database and Informatics Methods, Medicine and Health Sciences, Respiratory system, Young adult, lcsh:Science, Child, Respiratory Tract Infections, Phylogeny, Enterovirus, Multidisciplinary, Hematology, virus diseases, Phylogenetic Analysis, Immunosuppression, Coxsackieviruses, Middle Aged, Viral Persistence and Latency, Infectious Diseases, Medical Microbiology, Viral Pathogens, Child, Preschool, Viruses, RNA, Viral, Female, Pathogens, Sequence Analysis, Research Article, Adult, medicine.medical_specialty, Adolescent, Bioinformatics, Immunology, 030106 microbiology, Rhinovirus Infection, Research and Analysis Methods, Microbiology, Immune Suppression, Immunocompromised Host, Young Adult, 03 medical and health sciences, Signs and Symptoms, Diagnostic Medicine, Virology, Internal medicine, Enterovirus Infections, medicine, Humans, Molecular Biology Techniques, Molecular Biology, Microbial Pathogens, Aged, Retrospective Studies, Molecular Biology Assays and Analysis Techniques, Picornaviridae Infections, Biology and life sciences, business.industry, lcsh:R, Organisms, Infant, Newborn, Infant, Correction, Retrospective cohort study, Molecular Typing, Enterovirus Infection, 030104 developmental biology, Respiratory Infections, lcsh:Q, business, Sequence Alignment
Abstract

Several species of the genus Enterovirus cause persistent infections in humans. Human rhinovirus (HRV) infections are generally self-limiting but occasionally persistent infections have been described. This study aimed to identify persistent HRV infections and investigate the clinical and virologic characteristics of patients with persistent infections. From January 2012 to March 2015, 3714 respiratory specimens from 2608 patients were tested for respiratory viruses by using a multiplex reverse transcription–polymerase chain reaction. A retrospective study was performed. Patients with at least two specimens positive for HRV/enterovirus taken 45 days or longer apart were identified and the HRV/enteroviruses were typed. Patients with persistent infection were compared to patients with reinfection and patients with cleared infection. Phylogenetic analysis of the viral protein(VP)4/VP2 region was performed. 18 patients with persistent HRV/enterovirus infection were identified. Minimum median duration of persistence was 92 days (range 50–455 days). All but one patients with persistence were immunosuppressed. Immunosuppression and hematologic disorders were more frequent in patients with persistence (n = 18) than in patients with reinfection (n = 33) and with cleared infection (n = 25) (p = 0.003 and p = 0.001, respectively). In conclusion, this retrospective study identified HRV persistence in vivo which occurred mainly in immunosuppressed patients.

17. The Prognostic Impact of the Donor/Recipient CMV Serostatus in Patients with Different Chronic Hematological Disorders after Allogeneic Hematopoietic Stem Cell Transplantation: A Report from the Infectious Diseases Working Party of EBMT

Author

Schmidt-Hieber, Martin, Tridello, Gloria, Mikulska, Malgorzata, Knelange, Nina, Blaise, Didier, Socie, Gerard, Volin, Liisa, Nicolaas Schaap, Fegueux, Nathalie, Ljungman, Per, Yakoub-Agha, Ibrahim, Milpied, Noel, Maertens, Johan, Chevallier, Patrice, Passweg, Jakob R., Cornelissen, Jan J., Russell, Nigel H., Craddock, Charles, Bourhis, Jean-Henri, Lamy, Thierry, Remenyi, Peter, Cahn, Jean-Yves, Michallet, Mauricette, Montoto, Silvia, Kroger, Nicolaus, Glass, Bertram, and Styczynski, Jan

20. Measurable Residual Disease, FLT3-ITD Mutation And Disease Status Have Independent Prognostic Influence on Post-Transplant Outcomes in NPM1-Mutated Acute Myeloid Leukemia

Author

Al Hamed, Rama, Labopin, Myriam, Deconinck, Eric, Nuttyvuopio, Rutta, Huynh, Anne, Socie, Gerard, Yakoub-Agha, Ibrahim, Bourhis, Jean Henri, Naim, Hassan, Tholouli, Eleni, Choi, Goda, Poire, Xavier, Martin, Hans, Rubio, Marie-Therese, Jindra, Pavel, Didier Blaise, Beelen, Dietrich, Labussiere-Wallet, Helene, Esteve, Jordi, Nagler, Arnon, Bazarbachi, Ali, and Mohty, Mohamad

21. Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients Aged >= 60 Years: a Retrospective Study of 629 Patients From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Author

Chevallier, Patrice, Didier Blaise, Milpied, Noel-Jean, Michallet, Mauricette, Vernant, Jean-Paul, Fegueux, Nathalie, Renaud, Marc, Rio, Bernard, Gratecos, Nicole, Cahn, Jean-Yves, Socie, Gerard, Yakoub-Agha, Ibrahim, Huynh, Anne, Francois, Sylvie, Bay, Jacques-Olivier, Cordonnier, Catherine, Buzyn, Agnes, Contentin, Nathalie, Deconinck, Eric, and Mohty, Mohamad

22. Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Author

Jacobson, Caron, Chavez, Julio C., Sehgal, Alison R., William, Basem M., Munoz, Javier, Gilles Salles, Munshi, Pashna N., Casulo, Carla, Maloney, David, Vos, Sven, Reshef, Ran, Leslie, Lori A., Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Fung, Henry C. H., Rosenblatt, Joseph D., Rossi, John M., Goyal, Lovely, Plaks, Vicki, Yang, Yin, Lee, Jennifer, Godfrey, Wayne, Vezan, Remus, Avanzi, Mauro P., and Neelapu, Sattva S.

24. Association Between Multiple Mismatches at the HLA-DPB1 and DRB3/4/5 Genes and Adverse Outcomes in HLA-a, -B, -C,-DRB1 and-DQB1 Identical Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI)

Author

Ducreux, Stephanie, Dubois, Valerie, Loiseau, Pascal, Yakoub-Agha, Ibrahim, Myriam LABALETTE, Michallet, Mauricette, Rubio, Marie T., Kennel, Anne, Forcade, Edouard, Lafarge, Xavier, Cahn, Jean-Yves, Masson, Dominique, Daguindau, Etienne, Dormoy, Anne, Maillard, Natacha, Jollet, Isabelle, Chevallier, Patrice, Cesbron, Anne, Bay, Jacques-Olivier, Quainon, Fabienne, Amokrane, Kahina, Socie, Gerard, Porcher, Raphael, and Latour, Regis Peffault

26. Single HLA Mismatch Unrelated Donor Allogeneic Stem Cell Transplantation in Caucasian Recipients: Outcomes in HLA-A, -B, -C,-DRB1 and-DQB1 Mismatch Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI)

Author

Loschi, Michael, Furst, Sabine, Tabrizi, Reza, Michallet, Mauricette, Fegueux, Nathalie, Yakoub-Agha, Ibrahim, Maury, Sebastien, Bulabois, Claude-Eric, Bourhis, Jean-Henri, Chevallier, Patrice, Bay, Jacques-Olivier, Loiseau, Pascale, Picard, Christophe, Lafarge, Xavier, Dubois, Valerie, Eliaou, Jean-Francois, Myriam LABALETTE, Harfouch, Elham, Delbos, Florent, Masson, Dominique, Cesbron, Anne, Quainon, Fabienne, Socie, Gerard, Porcher, Raphael, and Latour, Regis Peffault

27. Role of Allogeneic Reduced Intensity Conditioning Stem Cell Transplantation (RIC-SCT) in Older Patients with Acute Myeloid Leukemia (AML): Analysis of the ALFA-1200 Study

Author

Gardin, Claude, Pautas, Cecile, Lemasle, Emilie, Bourhis, Jean-Henri, Ades, Lionel, Marolleau, Jean-Pierre, Malfuson, Jean Valere, Gastaud, Lauris, Raffoux, Emmanuel, Cano, Isabel, Braun, Thorsten, Thomas, Xavier, Chantepie, Sylvain, Cluzeau, Thomas, Botton, Stephane, Berthon, Celine, Papoular, Benjamin, Boissel, Nicolas, Claude Preudhomme, Terre, Christine, Socie, Gerard, Michallet, Mauricette, Yakoub-Agha, Ibrahim, Celli-Lebras, Karine, and Dombret, Herve

28. Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study

Author

Ibrahim Yakoub-Agha, Dirk-Jan Eikema, Silvia Montoto, Hildegard Greinix, Arnon Nagler, Mohamad Mohty, Marie Robin, Yves Chalandon, Stephen D. Robinson, Christian Chabannon, Nicolaus Kröger, Liesbeth C. de Wreede, Francesco Lanza, Stefan Schönland, Malgorzata Mikulska, Zinaida Peric, Olaf Penack, Linda Koster, Annalisa Ruggeri, Grzegorz W. Basak, Jan Styczyński, Greinix, Hildegard T, Eikema, Dirk-Jan, Koster, Linda, Penack, Olaf, Yakoub-Agha, Ibrahim, Montoto, Silvia, Chabannon, Christian, Styczynski, Jan, Nagler, Arnon, Robin, Marie, Robinson, Stephen, Chalandon, Yve, Mikulska, Malgorzata, Schönland, Stefan, Peric, Zinaida, Ruggeri, Annalisa, Lanza, Francesco, De Wreede, Liesbeth C, Mohty, Mohamad, Basak, Grzegorz W, and Kröger, Nicolaus

Subjects
Male, medicine.medical_specialty, Graft vs Host Disease, Disease, survival, Graft vs Host Disease* / prevention & control, prevention, Unrelated Donor, Internal medicine, medicine, Humans, Sibling, Alemtuzumab, ddc:616, Hematopoietic Stem Cell Transplantation* / adverse effects, Hematopoietic cell, business.industry, Incidence (epidemiology), Hematologic Neoplasms* / complications, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, medicine.disease, mortality, Graft vs Host Disease* / etiology, Transplantation, stem cell, diagnosi, Graft-versus-host disease, surgical procedures, operative, haploidentical bone marrow, Hematologic Neoplasms, Female, business, Unrelated Donors, Calendar time
Abstract

Acute graft-versus-host disease (aGvHD) remains a major threat to successful outcome following allogeneic hematopoietic cell transplantation though advances in prophylaxis and supportive care have been made. The aim of this study is to test whether the incidence and mortality of aGvHD have decreased over time. 102,557 patients with a median age of 47.6 years and with malignancies after first allogeneic sibling or unrelated donor (URD) transplant were studied in the following periods: 1990-1995, 1996-2000, 2001-2005, 2006-2010 and 2011-2015. Findings: 100-day incidences of aGvHD grades II-IV decreased from 40% to 38%, 32%, 29% and 28%, respectively, over calendar time (P

Published
2020

29. Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD

Author

Christophe Picard, Cécile Macquin, Sergi Querol, Catherine Paillard, Katharina Fleischhauer, Gaëlle Giacometti, Bronno van der Holt, Ibrahim Yakoub-Agha, Wassila Ilias, Anne Cesbron, Myriam Labopin, Masao Ota, Jorge Sierra, Fabio Ciceri, Dominique Charron, Ryad Tamouza, Régis Peffault de Latour, Xavier Lafarge, Katia Gagne, Seiamak Bahram, Myriam Maumy-Bertrand, Meiggie Untrau, Pascale Loiseau, Raphael Carapito, Jürgen Kuball, Bruno Lioure, Frans H.J. Claas, Noel Milpied, Antoine Toubert, Jan J. Cornelissen, Irina Kotova, Philippe Moreau, Eric Spierings, Mauricette Michallet, Arnon Nagler, Annette Schmitt-Graeff, Angélique Pichot, Petya Apostolova, Mohamad Mohty, Aurore Morlon, Myriam Labalette, Nicolas Jung, Didier Blaise, Yoshihiko Katsuyama, Hidetoshi Inoko, A. Parissiadis, Frédéric Bertrand, Marius Kwemou, Sandra Michel, Machteld Oudshoorn, Gérard Socié, Robert Zeiser, Peter A. von dem Borne, Valérie Dubois, Luca Vago, Carapito, Raphael, Jung, Nicola, Kwemou, Mariu, Untrau, Meiggie, Michel, Sandra, Pichot, Angélique, Giacometti, Gaëlle, Macquin, Cécile, Ilias, Wassila, Morlon, Aurore, Kotova, Irina, Apostolova, Petya, Schmitt Graeff, Annette, Cesbron, Anne, Gagne, Katia, Oudshoorn, Machteld, Van Der Holt, Bronno, Labalette, Myriam, Spierings, Eric, Picard, Christophe, Loiseau, Pascale, Tamouza, Ryad, Toubert, Antoine, Parissiadis, Anne, Dubois, Valérie, Lafarge, Xavier, Maumy Bertrand, Myriam, Bertrand, Frédéric, Vago, Luca, Ciceri, Fabio, Paillard, Catherine, Querol, Sergi, Sierra, Jorge, Fleischhauer, Katharina, Nagler, Arnon, Labopin, Myriam, Inoko, Hidetoshi, Von Dem Borne, Peter A., Kuball, Jürgen, Ota, Masao, Katsuyama, Yoshihiko, Michallet, Mauricette, Lioure, Bruno, De Latour, Régis Peffault, Blaise, Didier, Cornelissen, Jan J., Yakoub Agha, Ibrahim, Claas, Fran, Moreau, Philippe, Milpied, Noël, Charron, Dominique, Mohty, Mohamad, Zeiser, Robert, Socié, Gérard, Bahram, Seiamak, inconnu, Inconnu, Institut de Recherche Mathématique Avancée (IRMA), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Mathématiques et Modélisation d'Evry (LaMME), Institut National de la Recherche Agronomique (INRA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), laboratoire d'Etudes et de recherches en Statistiques et Développement (LERSTAD), Université Gaston Bergé Sénégal, Laboratoire d'Acoustique Environnementale (IFSTTAR/AME/LAE), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-Université de Lyon-PRES Université Nantes Angers Le Mans (UNAM), Physique des interactions ioniques et moléculaires (PIIM), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), LabEx Transplantex [Strasbourg], Université de Strasbourg (UNISTRA), Etablissement Français du Sang [Nantes], Etablissement Français du Sang - Alpes-Méditerranée (EFS - Alpes-Méditerranée), Etablissement Français du Sang, Service de pneumologie [Rennes] = Pneumology [Rennes], CHU Pontchaillou [Rennes], Anthropologie bio-culturelle, Droit, Ethique et Santé (ADES), Aix Marseille Université (AMU)-EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique (CNRS), Alloimmunité-Autoimmunité-Transplantation (A2T), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hématologie -Immunologie -Cibles thérapeutiques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Sociétés, Acteurs, Gouvernement en Europe (SAGE), Politique, Religion, Institutions et Sociétés : Mutations Européennes - Groupe de Sociologie Politique Européenne (PRISME-GSPE), Centre National de la Recherche Scientifique (CNRS), Centre de Transfusion Sanguine Aquitaine-Limousin (CTS AQUITAINE-LIMOUSIN), Centre de Transfusion Sanguine, Ospedale San Raffaele, Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Barcelona Cord Blood Bank, Agrosystèmes tropicaux (ASTRO), Institut National de la Recherche Agronomique (INRA), Chaim Sheba Medical Center [Ramat Gan, Israel], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Université Paris Diderot - Paris 7 (UPD7), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Immunohematology and Blood Transfusion, Leiden University Medical Center (LUMC), Universiteit Leiden-Universiteit Leiden, Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d'Investigations Biomédicales-Hématologie, Oncologie et Greffes (CIB-HOG), Hôpital St Louis, Assistance Publique des Hôpitaux de Paris (AP-HP), Centre d'Investigations Biomédicales-Hématologie, Institut National de la Recherche Agronomique (INRA)-Université d'Évry-Val-d'Essonne (UEVE)-ENSIIE-Centre National de la Recherche Scientifique (CNRS), Service de pneumologie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), ALWP-EBMT & Département d'hématologie et de thérapie cellulaire [AP-HP Hôpital Saint-Antoine], AP-HP - Hôpital Saint-Antoine, Hematology, Institut de Recherche Mathématique Avancée ( IRMA ), Université de Strasbourg ( UNISTRA ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Strasbourg ( UNISTRA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de Mathématiques et Modélisation d'Evry ( LaMME ), Institut National de la Recherche Agronomique ( INRA ) -Université d'Évry-Val-d'Essonne ( UEVE ) -ENSIIE-Centre National de la Recherche Scientifique ( CNRS ), laboratoire d'Etudes et de recherches en Statistiques et Développement ( LERSTAD ), Laboratoire d'Acoustique Environnementale ( IFSTTAR/AME/LAE ), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux ( IFSTTAR ) -Université de Lyon-PRES Université Nantes Angers Le Mans ( UNAM ), Laboratoire d'Histoire des Sciences et de Philosophie - Archives Henri Poincaré ( LHSP ), Université de Lorraine ( UL ) -Centre National de la Recherche Scientifique ( CNRS ), Physique des interactions ioniques et moléculaires ( PIIM ), Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Functional Genomics and Cancer, Etablissement Français du Sang - Alpes-Méditerranée ( EFS - Alpes-Méditerranée ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CHU Pontchaillou [Rennes], Anthropologie bio-culturelle, Droit, Ethique et Santé ( ADES ), Aix Marseille Université ( AMU ) -EFS ALPES MEDITERRANEE-Centre National de la Recherche Scientifique ( CNRS ), Alloimmunité-Autoimmunité-Transplantation ( A2T ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ), Sociétés, Acteurs, Gouvernement en Europe ( SAGE ), Politique, Religion, Institutions et Sociétés : Mutations Européennes - Groupe de Sociologie Politique Européenne ( PRISME-GSPE ), Centre National de la Recherche Scientifique ( CNRS ), Centre de Transfusion Sanguine Aquitaine-Limousin ( CTS AQUITAINE-LIMOUSIN ), Géographie de l'environnement ( GEODE ), Centre National de la Recherche Scientifique ( CNRS ) -Université Toulouse - Jean Jaurès ( UT2J ), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie ( UPMC ), Université Pierre et Marie Curie - Paris 6 ( UPMC ), Agrosystèmes tropicaux ( ASTRO ), Institut National de la Recherche Agronomique ( INRA ), Hospices Civils de Lyon ( HCL ), IFR Saint-Louis, institut d'hématologie ( ISLIH ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Erasmus MC University medical Centre / Daniel den Hoed Cancer centre, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Laboratoire de Mathématiques et Modélisation d'Evry, PRES Université Nantes Angers Le Mans (UNAM)-Université de Lyon-Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Strasbourg (UNISTRA), Centre National de la Recherche Scientifique (CNRS)-ENSIIE-Université d'Évry-Val-d'Essonne (UEVE)-Institut National de la Recherche Agronomique (INRA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7), Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0301 basic medicine, Male, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Medizin, Graft vs Host Disease, Hematopoietic stem cell transplantation, Biochemistry, Linkage Disequilibrium, immune system diseases, HLA Antigens, Cytotoxic T cell, Child, ComputingMilieux_MISCELLANEOUS, HLA-DQB1, biology, Histocompatibility Testing, Incidence, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Allografts, 3. Good health, surgical procedures, operative, NK Cell Lectin-Like Receptor Subfamily K, Child, Preschool, Acute Disease, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Adult, Adolescent, Immunology, Human leukocyte antigen, 03 medical and health sciences, MHC class I, medicine, Journal Article, Humans, Aged, Retrospective Studies, Transplantation, [ SDV ] Life Sciences [q-bio], Histocompatibility Antigens Class I, Infant, Newborn, Infant, Cell Biology, medicine.disease, Histocompatibility, stomatognathic diseases, 030104 developmental biology, Graft-versus-host disease, Chronic Disease, biology.protein
Abstract

Graft-versus-host disease (GVHD) is among the most challenging complications in unrelated donor hematopoietic cell transplantation (HCT). The highly polymorphic MHC class I chain-related gene A, MICA, encodes a stress-induced glycoprotein expressed primarily on epithelia. MICA interacts with the invariant activating receptor NKG2D, expressed by cytotoxic lymphocytes, and is located in the MHC, next to HLA-B. Hence, MICA has the requisite attributes of a bona fide transplantation antigen. Using high-resolution sequence-based genotyping of MICA, we retrospectively analyzed the clinical effect of MICA mismatches in a multicenter cohort of 922 unrelated donor HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 10/10 allele-matched HCT pairs. Among the 922 pairs, 113 (12.3%) were mismatched in MICA. MICA mismatches were significantly associated with an increased incidence of grade III-IV acute GVHD (hazard ratio [HR], 1.83; 95% confidence interval [CI], 1.50-2.23; P < .001), chronic GVHD (HR, 1.50; 95% CI, 1.45-1.55; P < .001), and nonelapse mortality (HR, 1.35; 95% CI, 1.24-1.46; P < .001). The increased risk for GVHD was mirrored by a lower risk for relapse (HR, 0.50; 95% CI, 0.43-0.59; P < .001), indicating a possible graft-versus-leukemia effect. In conclusion, when possible, selecting a MICA-matched donor significantly influences key clinical outcomes of HCT in which a marked reduction of GVHD is paramount. The tight linkage disequilibrium between MICA and HLA-B renders identifying a MICA-matched donor readily feasible in clinical practice.

Published
2016

30. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1

Author

Didier Blaise, Anne Huynh, Jurjen Versluis, Arnon Nagler, Mauricette Michallet, Gérard Socié, Eric Deconinck, Annalisa Ruggeri, Patrice Chevallier, Charles Craddock, Ibrahim Yakoub-Agha, Liisa Volin, Jakob Passweg, Noel Milpied, Jan J. Cornelissen, Myriam Labopin, Per Ljungman, Depei Wu, Fabio Ciceri, Johan Maertens, Mohamad Mohty, Hematology, Versluis, Jurjen, Labopin, Myriam, Ruggeri, Annalisa, Socie, Gerard, Wu, Depei, Volin, Liisa, Blaise, Didier, Milpied, Noel, Craddock, Charle, Yakoub-Agha, Ibrahim, Maertens, Johan, Ljungman, Per, Huynh, Anne, Michallet, Mauricette, Deconinck, Eric, Chevallier, Patrice, Passweg, Jakob, Ciceri, Fabio, Mohty, Mohamad, Cornelissen, Jan J, Nagler, Arnon, Department of Medicine, Clinicum, and HUS Comprehensive Cancer Center

Subjects
medicine.medical_specialty, medicine.medical_treatment, Hematopoietic stem cell transplantation, Umbilical cord, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, parasitic diseases, medicine, In patient, Transplantation, Poor risk, business.industry, Complete remission, Myeloid leukemia, Hematology, 3. Good health, medicine.anatomical_structure, 3121 General medicine, internal medicine and other clinical medicine, 030220 oncology & carcinogenesis, Immunology, Stem cell, business, 030215 immunology
Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML). With increasing alternative donors available, the preferred donor or stem cell source is debated. We set out to study outcome in recipients of alloHSCT with poor-risk AML in first complete remission (CR1) by donor type. A total of 6545 adult patients with poor-risk AML in CR1 receiving an alloHSCT using matched related donor (MRD, n = 3511) or alternative donors, including 10/10 (n = 1959) or 9/10 matched unrelated donors (MUDs, n = 549), umbilical cord blood (UCB) grafts (n = 333), or haplo-identical (haplo) donors (n = 193) were compared. Overall survival (OS) at 2 years following MRD alloHSCT was an estimated 59 ± 1%, which did not differ from 10/10 MUD (57 ± 1%) and haplo alloHSCT (57 ± 4%). OS, however, was significantly lower for 9/10 MUD alloHSCT (49 ± 2%) and UCB grafts (44 ± 3%), respectively (P < .001). Nonrelapse mortality (NRM) depended on donor type and was estimated at 26 ± 3% and 29 ± 3% after haplo alloHSCT and UCB grafts at 2 years vs 15 ± 1% following MRD alloHSCT. Multivariable analysis confirmed the impact of donor type with OS following MRD, 10/10 MUD, and haplo alloHSCT not being statistically significantly different. NRM was significantly higher for alternative donors as compared with MRD alloHSCT. Collectively, these results suggest that alloHSCT with MRDs and 10/10 MUDs may still be preferred in patients with poor-risk AML in CR1. If an MRD or 10/10 MUD is not available, then the repertoire of alternative donors includes 9/10 MUD, UCB grafts, and haplo-identical donors. The latter type of donor is increasingly applied and now approximates results with matched donors. ispartof: BLOOD ADVANCES vol:1 issue:7 pages:477-485 ispartof: location:United States status: published

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results